Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Med Oncol ; 27(3): 702-7, 2010 Sep.
Article in English | MEDLINE | ID: mdl-19669610

ABSTRACT

Acute promyelocytic leukemia (APL) is one of the most curable myeloid malignancies because of its great sensitivity to all-trans retinoic acid (ATRA) and response to anthracycline therapy. In an attempt to simplify post-remission therapy, deliver adequate dose of anthracycline and reduce treatment related toxicity, we entered 26 consecutively newly diagnosed, previously untreated APL patients in a pilot treatment program consisting of concurrent induction using idarubicin/ATRA followed by an exclusive outpatient post-remission therapy using single dose of idarubicin and intermittent ATRA, every 4 weeks. Of 25 evaluable patients, two (8%) died early during induction due to hemorrhagic complications, and 23 (92%) achieved complete remission. Overall survival at 4.2 years was 90% (CI 76.4-100), and 3.6 years disease-free survival was 78% (CI 60.6-95.4). The treatment outcome of this program is encouraging; however, the result of this study needs to be validated in larger cohort of patients and optimally in a randomized comparison with other current post-remission approaches.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Leukemia, Promyelocytic, Acute/drug therapy , Adolescent , Adult , Aged , Ambulatory Care , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Clinical Trials as Topic/statistics & numerical data , Dexamethasone/administration & dosage , Disease-Free Survival , Drug Administration Schedule , Factor VIII/therapeutic use , Female , Fibrinogen/analysis , Fibrinogen/therapeutic use , Hemorrhage/chemically induced , Hemorrhage/drug therapy , Humans , Idarubicin/administration & dosage , Idarubicin/adverse effects , Kaplan-Meier Estimate , Male , Middle Aged , Pilot Projects , Remission Induction , Tretinoin/administration & dosage , Tretinoin/adverse effects , Young Adult
2.
Bone Marrow Transplant ; 41(3): 287-91, 2008 Feb.
Article in English | MEDLINE | ID: mdl-17982501

ABSTRACT

Hepatic veno-occlusive disease (VOD) is one of the most common and important regimen-related toxicities observed after hematopoietic stem cell transplantation (HSCT). There are no universally accepted preventative or therapeutic approaches for VOD. We prospectively evaluated the safety and efficacy of a short course of methylprednisolone (MP) in 48 patients undergoing allogeneic HSCT who were diagnosed with hepatic VOD. MP was administered at a dose of 0.5 mg/kg i.v. every 12 h for a total of 14 doses, and then discontinued without taper. Thirty (63%) patients responded with a reduction in total serum bilirubin of 50% or more after 10 days of treatment. In univariate analysis, non-responders had a higher total bilirubin at the start of MP therapy, more weight gain, evidence of fungal infection and platelet refractoriness. High SGPT and early engraftment were significant factors among responders. Twenty-five of the 30 responders survived up to day +100, whereas all but three non-responders died within 100 days post-HSCT, for a probability of survival of 58% among responders and 10% for non-responders. Prospective comparative studies are needed to confirm the observed encouraging outcome of MP therapy for VOD.


Subject(s)
Anti-Inflammatory Agents/administration & dosage , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/drug therapy , Methylprednisolone/administration & dosage , Drug Administration Schedule , Female , Humans , Male , Myeloablative Agonists/adverse effects , Pilot Projects , Prospective Studies , Transplantation Conditioning/adverse effects , Transplantation, Homologous/adverse effects
4.
Hematology ; 9(2): 123-9, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15203867

ABSTRACT

Between March 1984 and December 1999, a total of 43 second related allogeneic BMT procedures after myeloablative conditioning were carried out in our institution, 37 following allogeneic, and 6 following autologous BMT. Thirty one patients were males (72%). At 1st BMT (BMT1), median age was 11.5 years (range, 0.16-45 years). BMT1 was carried out for the diagnosis of AML in 13 patients (30%), SAA in nine (21%), ALL in six (14%), CML in six (14%), immunodeficiency in three (7%), NHL in two, beta-thal in two, HD in one, Red cell aplasia in one. HLA matching status for allogeneic BMT1 was full match in 33, one antigen mismatch in two and haplo identical in two patients. Median age at the 2nd BMT (BMT2) was 14 years (range, 0.41-46.7 years). Indications for BMT2 were recurrent hematologic neoplasm in 23 patients (53%), primary graft failure in 12 (28%) and late graft failure in 8 (19%). Median time from BMT1 to recurrence of hematologic neoplasm or late graft failure was 10 months (range, 2.5- 88 months). Median BMT1 to BMT2 interval was 13 months (range, 1-107 months). For BMT2, the same donor was used in 29 patients, while 14 patients had alternate related donor (12 full match, 1-one Ag mismatch, 1 haplo identical). A different conditioning regimen was used in the majority of the patients (39, 91%). Radiation containing conditioning regimen were used mostly for patients previously conditioned with chemotherapy only for BMT1 and chemotherapy conditioning +/- ATG for those who received radiation containing conditioning at BMT1. Bone marrow was the stem cell source for all patients at BMT2 and all except three autologous peripheral stem cell transplantation patient at BMT1. Significant organ toxicity leading to procedure related death in 13 patients (30%) was observed after BMT2. At a median follow up of 36 months after BMT2, 22 patients (51%) are alive (20 free of disease, 2 with recurrent disease) with overall median survival of 47.5 (SD +/- 9) months. Univariate analysis of relevant clinical factors identified the following variables as the only statistically significant favorable prognostic factors for overall survival: BMT1-BMT2 interval of > or = 6 months (P=0.0007) and age at BMT2 < or = 10 years (P=0.041). The nature of underlying disease (neoplastic or non-neoplastic) was not statistically significant (P=0.23). There was no statistically significant difference in survival outcome of BMT2 using same donor vs. alternate related donor (P=0.51). Due to the relatively limited sample size, multivariate analysis was not attempted. This single institution study suggests that second allogeneic BMT after myeloblative conditioning has an acceptable treatment related morbidity/mortality and favorable outcome if performed at age < or = 10 years and with an interval of > or = 6 months after the first BMT. Additionally same donor can successfully be used for the second transplant with similar survival outcome to alternate donor.


Subject(s)
Anemia, Aplastic/surgery , Leukemia, Myeloid, Acute/surgery , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Transplantation Conditioning/methods , Adolescent , Adult , Anemia, Aplastic/mortality , Bone Marrow Transplantation , Child , Child, Preschool , Female , Humans , Infant , Leukemia, Myeloid, Acute/mortality , Male , Middle Aged , Postoperative Complications/classification , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Reoperation , Retrospective Studies , Survival Analysis , Time Factors , Transplantation, Autologous , Transplantation, Homologous
SELECTION OF CITATIONS
SEARCH DETAIL
...